Finally, we revealed that targeting the 14-3-3η/ NF-κB feedback loop using our novel 14-3-3η inhibitor (imICA) could prevent DEHP-induced HOD. Here, NFKB1 is linked to hypopigmentation, organomegaly, and delayed myelination and development.